Therapies that inhibit vascular endothelial growth factor (VEGF), ‘anti-VEGFs’, play a key role in reducing angiogenesis and vascular permeability [1] with the aim to prevent sight loss in ocular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO), macular oedema caused by retinal vein occlusion and myopic choroidal neovascularisation (myopic CNV). Here, VEGFA is linked to wet macular degeneration.